TLR7 and neoplasm: TLR7-deficient (TLR7-/-) mice bearing B16 melanoma tumors treated with FluVx did not experience reduction in tumor progression which was found in TLR7-competent, C57BL/6J (WT) mice (Figures 2A, B).